CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SciClone Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SciClone Pharmaceuticals, Inc.
950 Tower Lane
Suite 900
Phone: (650) 358-3456p:650 358-3456 Foster City, CA  94404-2125  United States Fax: (650) 358-3469f:650 358-3469

This company ceased filing statements with the SEC on 10/25/2017.

Business Summary
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-YesYes----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201712/31/2016YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Jon S.Saxe 79 7/29/2009 8/1/2000
President, Chief Executive Officer, Director FriedhelmBlobel 66 7/16/2013 6/2/2006
Chief Financial Officer, Senior Vice President - Finance, Secretary Wilson W.Cheung 46 7/16/2013 7/16/2013
7 additional Officers and Directors records available in full report.

Business Names
Business Name
NOVAMED PHARMACEUTICALS (SHANGHAI) CO. LTD.
SCICLONE PHARMACEUTICALS (CHINA) CO. LTD.
SCICLONE PHARMACEUTICALS (CHINA) LTD
8 additional Business Names available in full report.

General Information
Number of Employees: 570 (As of 12/31/2016)
Outstanding Shares: 52,191,854 (As of 6/30/2017)
Shareholders: 190
Stock Exchange: NASD
Federal Tax Id: 943116852
Fax Number: (650) 358-3469
Email Address: ir@sciclone.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023